Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.

BMC medicine - 26 Aug 2020

Tian Yanhua, Xu Jiachen, Chu Qian, Duan Jianchun, Zhang Jianjun, Bai Hua, Yang Zhenlin, Fang Wenfeng, Cai Liangliang, Wan Rui, Fei Kailun, He Jie, Gao Shugeng, Zhang Li, Wang Zhijie, Wang Jie

Abstract excerpt

BACKGROUND: Tumor mutational burden (TMB) has both prognostic value in resected non-small cell lung cancer (NSCLC) patients and predictive value for immunotherapy response. However, TMB evaluation by whole-exome sequencing (WES) is expensive and time-consuming, hampering its application in clinical practice. In our study, we aimed to construct a mutational burden estimation model, with a small set of genes, that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Cancer Immunotherapy and Biomarkers

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Immunotherapy

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Share to Survival Analysis

Source

Open in PubMed Open full text

Identifiers

PMID: 32843031
DOI: 10.1186/s12916-020-01694-8
PMCID: PMC7448445

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patients.PMID 32843031Read ↗

Integrating Histologic and Genomic Characteristics to Predict Tumor Mutation Burden of Early-Stage Non-Small-Cell Lung CancerSemantic proximity Read ↗

Integrative modeling of multi-omics data for predicting tumor mutation burden in lung cancer patientsSemantic proximity Read ↗

Integrative Modeling of Multiomics Data for Predicting Tumor Mutation Burden in Patients with Lung Cancer.Semantic proximity Read ↗

The landscape of tumor mutational burden and its clinical significance in patients with lung cancer: a Multi-omics study with a meta-analysisSemantic proximity Read ↗

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-makingSemantic proximity Read ↗

Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung AdenocarcinomasSemantic proximity Read ↗

Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report.Semantic proximity Read ↗

Mutation load estimation model as a predictor of the response to cancer immunotherapySemantic proximity Read ↗

Clinical and technical insights of tumour mutational burden in non-small cell lung cancer.Semantic proximity Read ↗

Tumor mutation burden and immunological, genomic, and clinicopathological factors as biomarkers for checkpoint inhibitor treatment of patients with non-small-cell lung cancer.Semantic proximity Read ↗

Prognostic value of tumor mutation burden in non-small cell lung cancer: A Meta-Analysis and system reviewSemantic proximity Read ↗

Blood tumor mutation burden can predict the clinical response to immune checkpoint inhibitors in advanced non-small cell lung cancer patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.